Literature DB >> 33400088

Herpesviruses and the Type III Interferon System.

Yue Yin1, Herman W Favoreel2.   

Abstract

Type III interferons (IFNs) represent the most recently discovered group of IFNs. Together with type I IFNs (e.g. IFN-α/β), type III IFNs (IFN-λ) are produced as part of the innate immune response to virus infection, and elicit an anti-viral state by inducing expression of interferon stimulated genes (ISGs). It was initially thought that type I IFNs and type III IFNs perform largely redundant functions. However, it has become evident that type III IFNs particularly play a major role in antiviral protection of mucosal epithelial barriers, thereby serving an important role in the first-line defense against virus infection and invasion at contact areas with the outside world, versus the generally more broad, potent and systemic antiviral effects of type I IFNs. Herpesviruseses are large DNA viruses, which enter their host via mucosal surfaces and establish lifelong, latent infections. Despite the importance of mucosal epithelial cells in the pathogenesis of herpesviruses, our current knowledge on the interaction of herpesviruses with type III IFN is limited and largely restricted to studies on the alphaherpesvirus herpes simplex virus (HSV). This review summarizes the current understanding about the role of IFN-λ in the immune response against herpesvirus infections.
© 2021. Wuhan Institute of Virology, CAS.

Entities:  

Keywords:  Herpes simplex virus (HSV); Herpesvirus; Innate immunity; Type III interferon (IFN-λ)

Mesh:

Substances:

Year:  2021        PMID: 33400088      PMCID: PMC8379308          DOI: 10.1007/s12250-020-00330-2

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  69 in total

1.  Genomewide function conservation and phylogeny in the Herpesviridae.

Authors:  M M Albà; R Das; C A Orengo; P Kellam
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

2.  The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.

Authors:  Stéphanie Bibert; Agnieszka Wojtowicz; Patrick Taffé; Oriol Manuel; Enos Bernasconi; Hansjakob Furrer; Huldrych F Günthard; Matthias Hoffmann; Laurent Kaiser; Michael Osthoff; Matthias Cavassini; Pierre-Yves Bochud
Journal:  AIDS       Date:  2014-08-24       Impact factor: 4.177

3.  Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo.

Authors:  Nina Ank; Hans West; Christina Bartholdy; Kristina Eriksson; Allan R Thomsen; Søren R Paludan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

5.  Cross-species antiviral activity of goose interferon lambda against duck plague virus is related to its positive self-regulatory feedback loop.

Authors:  Shun Chen; Wei Zhang; Qin Zhou; Anqi Wang; Lipei Sun; Mingshu Wang; Renyong Jia; Dekang Zhu; Mafeng Liu; Kunfeng Sun; Qiao Yang; Ying Wu; Xiaoyue Chen; Anchun Cheng
Journal:  J Gen Virol       Date:  2017-06       Impact factor: 3.891

6.  Modes of action of lipid-lowering diets in man: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition.

Authors:  C Cortese; Y Levy; E D Janus; P R Turner; S N Rao; N E Miller; B Lewis
Journal:  Eur J Clin Invest       Date:  1983-02       Impact factor: 4.686

7.  Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients.

Authors:  Dayana Bravo; Carlos Solano; Estela Giménez; María José Remigia; Isabel Corrales; Paula Amat; David Navarro
Journal:  J Med Virol       Date:  2013-12-27       Impact factor: 2.327

8.  mRNA expression of IFN-λs in the gingival tissue of patients with chronic or aggressive periodontitis: A polymerase chain reaction study.

Authors:  Shivaprasad Bilichodmath; Sruthi K Nair; Rekha Bilichodmath; Sachin B Mangalekar
Journal:  J Periodontol       Date:  2018-07       Impact factor: 6.993

9.  An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity.

Authors:  Nina Ank; Marie B Iversen; Christina Bartholdy; Peter Staeheli; Rune Hartmann; Uffe B Jensen; Frederik Dagnaes-Hansen; Allan R Thomsen; Zhi Chen; Harald Haugen; Kevin Klucher; Søren R Paludan
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  Reversible silencing of cytomegalovirus genomes by type I interferon governs virus latency.

Authors:  Franziska Dağ; Lars Dölken; Julia Holzki; Anja Drabig; Adrien Weingärtner; Johannes Schwerk; Stefan Lienenklaus; Ianina Conte; Robert Geffers; Colin Davenport; Ulfert Rand; Mario Köster; Siegfried Weiß; Barbara Adler; Dagmar Wirth; Martin Messerle; Hansjörg Hauser; Luka Cičin-Šain
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

View more
  4 in total

1.  Pseudorabies Virus Inhibits Type I and Type III Interferon-Induced Signaling via Proteasomal Degradation of Janus Kinases.

Authors:  Yue Yin; Nicolás Romero; Herman W Favoreel
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

2.  Coinfection of Porcine Circovirus 2 and Pseudorabies Virus Enhances Immunosuppression and Inflammation through NF-κB, JAK/STAT, MAPK, and NLRP3 Pathways.

Authors:  Xue Li; Si Chen; Liying Zhang; Guyu Niu; Xinwei Zhang; Lin Yang; Weilong Ji; Linzhu Ren
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

Review 3.  The gamble between oncolytic virus therapy and IFN.

Authors:  Qingbo Li; Fengxian Tan; Yuanyuan Wang; Xiaohui Liu; Xianbin Kong; Jingyan Meng; Long Yang; Shan Cen
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

Review 4.  Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man.

Authors:  Anthony J St Leger; David M Koelle; Paul R Kinchington; Georges Michel G M Verjans
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.